Skip to main content

B2 Agonists and Their Safety in the Treatment of Asthma

Buy Article:

$39.50 plus tax (Refund Policy)

Abstract:

Increasing prevalence and severity of asthma has prompted the development and promulgation of various national and international guidelines for asthma management in adults and children. All of these guidelines agree that short-acting inhaled B2-agonists on demand represent the most appropriate initial bronchodilator therapy. However, there has been considerable debate as to the merit of maintenance bronchodilator therapy with regular inhaled B2-agonists, either the short acting agents, or the newer long-acting inhaled B2-agonist, salmeterol. Of concern is the possibility that there are detrimental effects of chronic B2-agonist bronchodilator treatment. Do these B2-agonists have the potential to worsen asthma control and there by have an adverse impact by contributing to the increased prevalence and severity of asthma? This article will review the pertinent literature with regard to the safety of the B2-agonists, which are appropriate but not perfect medications for asthmatics. It will also put this information in perspective for the clinician and provide this author's recommendations for their use in managing the manifestations of chronic and recurrent asthma.

Document Type: Research Article

DOI: https://doi.org/10.2500/108854195778702693

Publication date: 1995-09-01

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • www.AJRA.com
  • www.AllergyandRhinology.com
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more